Imran Ahmed, MD
Hematology & Oncology · Las Vegas, NVNPI 1679650949
Payments from drug & device makers
Across 162 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$506
- Novartis$392
- Exelixis Inc.$217
- Seagen Inc.$197
- Amgen$166
- E.r. Squibb & Sons, L.L.C.$155
- plus $2K from 36 others
What the payments were for
- Food & beverage$3,24294%
- Education$2206%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 34 | $506 |
| Novartis | 21 | $392 |
| Exelixis Inc. | 12 | $217 |
| Seagen Inc. | 4 | $197 |
| Amgen | 12 | $166 |
| E.r. Squibb & Sons, L.L.C. | 7 | $155 |
| Astellas Pharma US Inc | 4 | $152 |
| Boston Scientific | 1 | $150 |
| Neurocrine Biosciences, Inc. | 1 | $104 |
| GSK | 5 | $100 |
| Gilead | 4 | $89 |
| Array Biopharma Inc | 4 | $82 |
| Intuitive Surgical | 1 | $82 |
| Johnson & Johnson | 4 | $80 |
| Tempus AI, Inc | 4 | $78 |
| EMD Serono, Inc. | 4 | $73 |
| Pfizer | 3 | $70 |
| Merck | 3 | $63 |
| AstraZeneca(2 entities) | 3 | $54 |
| Sanofi | 2 | $54 |
| Boehringer Ingelheim | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Genmab U.S., Inc. | 2 | $50 |
| Mirati Therapeutics, Inc. | 3 | $50 |
| Servier Pharmaceuticals LLC | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Sobi, Inc | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Beigene USA, Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Caris MPI, Inc. | 1 | $15 |
| Galvanize Therapeutics, Inc | 1 | $15 |
| AbbVie | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ICEfx Cryoablation System$150
- XTANDI$123
- INGREZZA$104
How this compares
$3,462 in reported general payments places this provider in the 20th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 48 | $790,762 |
| Lenalidomide | 53 | $697,632 |
| ImbruvicaIbrutinib | 39 | $634,018 |
| XtandiEnzalutamide | 25 | $368,942 |
| TagrissoOsimertinib Mesylate | 13 | $255,383 |
| SprycelDasatinib | 12 | $211,758 |
| BrukinsaZanubrutinib | 15 | $195,432 |
| Abiraterone Acetate | 34 | $65,184 |
| EliquisApixaban | 74 | $61,872 |
| XareltoRivaroxaban | 26 | $39,869 |
| Anastrozole | 92 | $1,867 |
| Oxycodone Hcl | 43 | $1,574 |
| Deferasirox | 12 | $1,462 |
| Hydroxyurea | 37 | $1,330 |
| Dexamethasone | 49 | $1,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $20 | $634,01839 claims |
| Astellas Pharma US IncXtandi | $152 | $368,94225 claims |
| AstraZenecaTagrisso | $54 | $255,38313 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $155 | $211,75812 claims |
| Beigene USA, Inc.Brukinsa | $25 | $195,43215 claims |
| PfizerEliquis | $70 | $61,87274 claims |
| Johnson & JohnsonXarelto | $80 | $39,86926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Edwin KingsleyLas Vegas$9.2M
- Nicholas VogelzangLas Vegas$8.3M
- Oscar GoodmanLas Vegas$6M
- Khawaja JahangirLas Vegas$2.5M
- Carolyn MulroneyLas Vegas$1.5M
- Wolfram SamlowskiLas Vegas$1.1M
- Anuradha ThummalaLas Vegas$736K
- Grzegorz ObaraLas Vegas$668K
- Aaron GoodmanLas Vegas$480K
- Vikas GuptaLas Vegas$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.